Plus Therapeutics, Inc. (PSTV) Bundle
Understanding Plus Therapeutics, Inc. (PSTV) Revenue Streams
Revenue Analysis
Financial data for the company reveals specific revenue insights for the most recent reporting periods.
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $4.23 million | -32.5% |
| 2023 | $3.91 million | -7.6% |
Revenue composition highlights the following key segments:
- Research and Development Services: 68% of total revenue
- Licensing Agreements: 22% of total revenue
- Collaboration Partnerships: 10% of total revenue
Detailed revenue stream breakdown demonstrates the following geographic distribution:
| Region | Revenue Contribution |
|---|---|
| United States | $3.42 million |
| Europe | $0.39 million |
| Asia-Pacific | $0.30 million |
Quarterly revenue trends indicate consistent challenges in maintaining stable income streams.
A Deep Dive into Plus Therapeutics, Inc. (PSTV) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational effectiveness and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -52.4% |
| Operating Margin | -276.5% | -239.1% |
| Net Profit Margin | -293.7% | -255.6% |
Key Profitability Observations
- Negative gross profit margin indicates challenges in core product/service pricing
- Consistent operating losses suggest ongoing operational inefficiencies
- Net profit margin demonstrates significant financial strain
Operational Efficiency Indicators
| Efficiency Metric | 2023 Performance |
|---|---|
| Research and Development Expenses | $14.2 million |
| Sales and Marketing Expenses | $3.7 million |
| General and Administrative Expenses | $9.5 million |
Comparative Industry Analysis
Profitability metrics significantly deviate from biotechnology industry median performance, indicating unique operational challenges.
Debt vs. Equity: How Plus Therapeutics, Inc. (PSTV) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Plus Therapeutics, Inc. demonstrates a complex financing approach with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $3.2 million | 45% |
| Total Short-Term Debt | $1.8 million | 25% |
| Total Debt | $5.0 million | 70% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 2.3:1
- Industry Average Debt-to-Equity Ratio: 1.5:1
- Variance from Industry Standard: +53%
Financing Strategy
The company's financing approach includes:
- Preferred equity issuance of $4.5 million
- Convertible debt instruments totaling $2.7 million
- Credit facility limit of $6 million
Recent Financing Activities
| Financing Type | Amount | Date |
|---|---|---|
| Equity Offering | $3.2 million | Q4 2023 |
| Debt Refinancing | $1.5 million | Q1 2024 |
Assessing Plus Therapeutics, Inc. (PSTV) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for the company's financial health as of the most recent reporting period.
| Liquidity Metric | Value | Period |
|---|---|---|
| Current Ratio | 0.41 | Q4 2023 |
| Quick Ratio | 0.35 | Q4 2023 |
| Working Capital | -$5.1 million | Q4 2023 |
Cash flow statement analysis reveals the following key insights:
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | -$7.3 million | 2023 |
| Investing Cash Flow | -$1.2 million | 2023 |
| Financing Cash Flow | $6.5 million | 2023 |
Liquidity concerns include:
- Current ratio below 1.0, indicating potential short-term solvency challenges
- Negative working capital of $5.1 million
- Negative operating cash flow of $7.3 million
Key financial indicators suggest potential liquidity constraints requiring strategic financial management.
Is Plus Therapeutics, Inc. (PSTV) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical financial metrics that provide insights into its current market positioning and potential investment attractiveness.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.73 |
| Price-to-Book (P/B) Ratio | 0.94 |
| Enterprise Value/EBITDA | -4.82 |
Stock price performance over the past 12 months demonstrates significant volatility:
- 52-week low: $0.43
- 52-week high: $1.80
- Current stock price: $0.57
Analyst consensus provides the following insights:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
Dividend-related metrics indicate:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing Plus Therapeutics, Inc. (PSTV)
Risk Factors: Comprehensive Analysis
According to the company's latest SEC filings, several critical risk factors emerge:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Limited Cash Resources | $3.8 million cash balance as of Q3 2023 |
| Operational Risk | Clinical Trial Challenges | Potential delay in drug development timelines |
| Market Risk | Competitive Oncology Landscape | Intense competition in targeted therapeutic markets |
Key Operational Risks
- Potential regulatory approval delays for primary drug candidates
- Limited financial resources to complete clinical trial phases
- High research and development expenditure
- Potential intellectual property challenges
Financial Risk Indicators
Financial metrics highlighting potential risks:
- Net loss of $8.4 million in most recent fiscal quarter
- Research and development expenses: $4.2 million
- Negative operating cash flow of $6.7 million
Market and Competitive Risks
External market dynamics presenting significant challenges:
| Risk Element | Current Status |
|---|---|
| Oncology Market Competition | Multiple emerging therapeutic approaches |
| Funding Environment | Challenging capital raising conditions |
| Regulatory Landscape | Stringent FDA approval processes |
Strategic Risk Mitigation
- Focused clinical development strategy
- Continuous cost management initiatives
- Potential strategic partnerships
Future Growth Prospects for Plus Therapeutics, Inc. (PSTV)
Growth Opportunities for Plus Therapeutics, Inc.
The company's growth strategy focuses on advancing oncology therapeutics with specific emphasis on rare cancer treatments and innovative drug delivery technologies.
Key Growth Drivers
- Precision cancer therapy development targeting rare oncological indications
- Advanced nanoliposomal drug delivery platform
- Potential expansion into targeted radiotherapeutic treatments
Product Pipeline Investment
| Product | Development Stage | Potential Market Value |
|---|---|---|
| ReSPECT Clinical Program | Phase 2 Clinical Trials | $45 million estimated market potential |
| Radiopharmaceutical Platform | Preclinical Research | $120 million projected market opportunity |
Financial Growth Projection
Research and development expenditure for 2024: $8.2 million
Strategic Partnerships
- Collaboration with academic research institutions
- Potential pharmaceutical development partnerships
- Strategic licensing agreements for drug candidates
Market Expansion Strategy
Target market focus: Rare oncology treatment segment with $3.5 billion global market potential
Plus Therapeutics, Inc. (PSTV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.